Goldline Pharmaceutical
Goldline Pharmaceutical (GLPL) share price was ₹32.98 at the 27 Oct 2026 close; sector Healthcare. In the Mar 2026 quarter, revenue was ₹17.31 Cr and net profit was ₹2.76 Cr. Promoters held 57.29% of Goldline Pharmaceutical in May 2026.
Peer Comparison
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
| ₹1,766.10 | 35.03 | 4,23,747 Cr | 5.07 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,625.00 | 87.36 | 2,55,514 Cr | 15.24 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,595.50 | 72.14 | 1,74,798 Cr | 9.51 | 0.82% | 12.16% | 9.06% | 17,058 Cr | 2,156 Cr | |
| ₹2,183.00 | 107.86 | 1,17,950 Cr | 22.26 | 0.09% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,179.50 | 26.25 | 1,17,656 Cr | 4.34 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹1,340.80 | 34.73 | 1,11,914 Cr | 2.88 | 0.61% | 10.87% | 13.94% | 34,247 Cr | 3,184 Cr | |
| ₹1,370.60 | 32.84 | 1,10,725 Cr | 3.13 | 0.96% | 11.21% | 14.88% | 28,589 Cr | 3,356 Cr | |
| Goldline Pharmaceutical (this company) | — | — | — | — | — | — | — | — | — |
| Median 8 companies | ₹1,766.10 | 35.03 | 1,17,950 Cr | 5.07 | 0.61% | 13.79% | 17.94% | 28,515 Cr | 3,184 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100. How it works →
No Tapetide Score has been computed for this stock yet.
Key Insights
Strengths
1- Company has a good return on equity (ROE) track record: 3 Years ROE 38.9%
Weaknesses
1- Company has high debtors of 189 days.
Technical Indicators
Oscillators
Bearish
Overall
Bearish
Moving Averages
Neutral
Growth Rate
change over 1 year
change over 1 year
Quarterly Results
| Particulars | Sep 2025 | Mar 2026 |
|---|---|---|
| Sales | 13.89 | 17.31 |
| Expenses | 11.25 | 13 |
| Operating Profit | 2.64 | 4.31 |
| OPM % | 19.01% | 24.9% |
| Other Income | 0 | 0 |
| Interest | 0.67 | 0.65 |
| Depreciation | 0.12 | 0.12 |
| PBT | 1.85 | 3.54 |
| Tax % | 26.49% | 21.75% |
| Net Profit | 1.36 | 2.76 |
| EPS (₹) | 1.97 | 4 |
Profit & Loss
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 19.73 | 23.48 | 28.01 | 31.18 |
| Expenses | 17.32 | 19.14 | 21.86 | 24.09 |
| Operating Profit | 2.41 | 4.34 | 6.15 | 7.09 |
| OPM % | 12.21% | 18.48% | 21.96% | 22.74% |
| Other Income | -0.2 | -0.04 | -0.09 | 0 |
| Interest | 1.63 | 1.61 | 1.95 | 1.46 |
| Depreciation | 0.18 | 0.16 | 0.25 | 0.24 |
| PBT | 0.4 | 2.53 | 3.86 | 5.39 |
| Tax % | 37.5% | 28.46% | 26.42% | 23.38% |
| Net Profit | 0.26 | 1.81 | 2.83 | 4.12 |
| EPS (₹) | 1.3 | 7.87 | 4.1 | 5.97 |
| Div. Payout % | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 2 | 2.3 | 6.9 | 6.9 |
| Reserves | 2.08 | 3.76 | 1.55 | 5.54 |
| Borrowings | 12.64 | 12.94 | 12.85 | 10.97 |
| Other Liabilities | 2.67 | 3.93 | 4.88 | 5.47 |
| Total Liabilities | 19.39 | 22.93 | 26.18 | 28.88 |
| Fixed Assets | 2.5 | 2.95 | 2.89 | 2.71 |
| CWIP | 0 | 0.45 | 0 | 0 |
| Investments | 0.07 | 0.03 | 0.03 | 0.03 |
| Other Assets | 16.82 | 19.5 | 23.26 | 26.14 |
| Total Assets | 19.39 | 22.93 | 26.18 | 28.88 |
Cash Flow
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating | 2.39 | 2.92 | 3.18 | 2.81 |
| Investing | -1.04 | -1.11 | 0.16 | -0.06 |
| Financing | -1.44 | -1.08 | -2.89 | -3.4 |
| Net Cash Flow | -0.09 | 0.74 | 0.45 | -0.65 |
| Free Cash Flow | 1.38 | 1.81 | 3.35 | 2.75 |
| CFO/OP | 101 | 72 | 66 | 53 |
Ratios
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Debtor Days | 160 | 150 | 139 | 189 |
| Inventory Days | 336 | 450 | 229 | 202 |
| Days Payable | 54.47 | 98.62 | 69.62 | 60.29 |
| Cash Conversion Cycle | 441 | 501 | 299 | 331 |
| Working Capital Days | 144 | 133 | 134 | 156 |
| ROCE % | — | 23.4% | 29.28% | 30.64% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Goldline Pharmaceutical insights
53 extracted metrics + investor summaries across FY17–FY26.
Documents
Frequently Asked Questions about Goldline Pharmaceutical
What does Goldline Pharmaceutical Ltd do?
Where is Goldline Pharmaceutical Ltd (GLPL) listed?
Which sector does Goldline Pharmaceutical Ltd belong to?
What is the 52-week high and low of Goldline Pharmaceutical Ltd?
Company Information
Goldline Pharmaceuticals is engaged in the business of marketing pharmaceutical products under the brand name “Goldline.”[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/544759.md for Goldline Pharmaceutical Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.